United States 119th Congress Status: In Committee Bipartisan · 5 D · 4 R · 1 I cosponsors

S 229 — DTC Act of 2025

Last action — Read twice and referred to the Committee on Finance. (text: CR S337-338; Sponsor introductory remarks on measure: CR S337)

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the Senate. Introduced January 23, 2025. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the Senate.

Odds of enactment

Low chance

Based on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Advancing 42% · moderate confidence

  • In Committee

    Current position in the legislative process.

  • 10 sponsors

    1 primary, 9 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 3 parties (5 D · 4 R · 1 I) — cross-party backing.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

Summary

Drug-price Transparency for Consumers Act of 2025 or the DTC Act of 2025This bill requires consumer advertisements for prescription drugs and biological products to include certain price information if the drug or biologic is (1) covered under Medicare or Medicaid, and (2) required to include a risk summary under current law.Specifically, such advertisements must clearly and conspicuously disclose the wholesale price for a 30-day supply of the drug or biologic and may explain that a consumer may pay a different amount for the drug or biologic depending on the consumer's health insurance coverage.The requirement does not apply to advertisements for drugs or biologics with a wholesale cost of less than $35 for a one-month supply.Each violation of this requirement is subject to a civil penalty of not more than $100,000.

Bill Text

Action History

  1. Introduced in Senate

  2. Read twice and referred to the Committee on Finance. (text: CR S337-338; Sponsor introductory remarks on measure: CR S337)

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 9 co-sponsors · 537 not signed on

Sponsors (1)

Co-sponsors (9)

Not signed on (537)

537 members have not signed on to this bill.

Show all 537 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does S 229 do?
Drug-price Transparency for Consumers Act of 2025 or the DTC Act of 2025This bill requires consumer advertisements for prescription drugs and biological products to include certain price information if the drug or biologic is (1) covered under Medicare or Medicaid, and (2) required to include a risk summary under current law.Specifically, such advertisements must clearly and conspicuously disclose the wholesale price for a 30-day supply of the drug or biologic and may explain that a consumer may pay a different amount for the drug or biologic depending on the consumer's health insurance coverage.The requirement does not apply to advertisements for drugs or biologics with a wholesale cost of less than $35 for a one-month supply.Each violation of this requirement is subject to a civil penalty of not more than $100,000.
Who sponsors S 229?
S 229 is sponsored by Durbin, Richard J. (Democratic), Grassley, Chuck (Republican), King, Angus S., Jr. (Independent), Ernst, Joni (Republican), Smith, Tina (Democratic), Welch, Peter (Democratic), Blumenthal, Richard (Democratic), Baldwin, Tammy (Democratic), Tuberville, Tommy (Republican), and Hyde-Smith, Cindy (Republican).
What is the current status of S 229?
This bill is in committee in the Senate. Introduced January 23, 2025. It must pass committee before a floor vote.
Where can I track S 229?
Track S 229 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on S 229

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of S 229

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →